论文信息 - a Phase Iia Study Of Single-agent Mor208, An Fc-optimized Anti-cd19 Antibody, In Patients With Relapsed Or Refractory B-cell Non-hodgkin's Lymphoma : 140 - 字舞流文

a Phase Iia Study Of Single-agent Mor208, An Fc-optimized Anti-cd19 Antibody, In Patients With Relapsed Or Refractory B-cell Non-hodgkin's Lymphoma : 140

C. Buske | P. Zinzani | M. Winderlich | K. Blum | M. Provencio | T. Robak | A. Goy | Z. Nagy | W. Jurczak | K. Maddocks | R. Korolkiewicz